归柏化瘀胶囊联合坦索罗辛治疗慢性前列腺炎的临床研究  

Clinical study on Guibai Huayu Capsules combined with tamsulosin in treatment of chronic prostatitis

作　　者：李静 顾亚奇[3] 鲍国[4] LI Jing;GU Yaqi;BAO Guo(Department of Pharmacy,Xinhua Hospital of Huainan Xinhua Medical Group,Huainan 232001,China;Department of Pharmacy,Northern Hospital of Huainan Xinhua Medical Group,Huainan 232001,China;Department of Hepatobiliary Surgery,Xinhua Hospital of Huainan Xinhua Medical Group,Huainan 232001,China;Department of Urology,Xinhua Hospital of Huainan Xinhua Medical Group,Huainan 232001,China)

机构地区：[1]淮南新华医疗集团新华医院药械科,安徽淮南232001 [2]淮南新华医疗集团北方医院药械科,安徽淮南232001 [3]淮南新华医疗集团新华医院肝胆外科,安徽淮南232001 [4]淮南新华医疗集团新华医院泌尿外科,安徽淮南232001

出　　处：《现代药物与临床》2025年第1期172-176,共5页Drugs & Clinic

基　　金：安徽省高校教学研究项目(2021ljyxm0385)。

摘　　要：目的探讨慢性前列腺炎患者使用归柏化瘀胶囊联合盐酸坦索罗辛缓释胶囊治疗的临床疗效。方法选取2021年1月—2023年6月淮南新华医疗集团新华医院收治的130例慢性前列腺炎患者,按随机抽签法将患者随机分为对照组和治疗组,每组各65例。对照组口服盐酸坦索罗辛缓释胶囊,0.2 mg/次,1次/d。治疗组在对照组基础上口服归柏化瘀胶囊,3粒/次,3次/d。两组均持续治疗4周。比较两组临床疗效、慢性前列腺炎症状指数(NIH-CPSI)评分、前列腺体积、前列腺移行区体积、尿流动力学指标、前列腺液炎性因子水平。结果治疗组的总有效率为95.38%,较对照组的总有效率83.08%高(P<0.05)。治疗后,两组疼痛评分、排尿障碍评分、生活质量评分、NIH-CPSI总分均低于治疗前(P<0.05),且治疗组的疼痛评分、排尿障碍评分、生活质量评分、NIH-CPSI总分低于对照组(P<0.05)。治疗后,两组前列腺体积、前列腺移行区体积均低于治疗前(P<0.05),且治疗组的前列腺体积、前列腺移行区体积低于对照组(P<0.05)。治疗后,两组最大尿流率(MFR)、平均尿流率(AFR)高于治疗前,膀胱残余尿量(PVR)低于治疗前(P<0.05),且治疗组MFR、AFR高于对照组,PVR低于对照组(P<0.05)。治疗后,两组患者前列腺液肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)水平均显著降低(P<0.05),且治疗组的前列腺液TNF-α、IL-6、IL-8水平较对照组降低更显著(P<0.05)。结论归柏化瘀胶囊联合盐酸坦索罗辛缓释胶囊治疗慢性前列腺炎患者,可减轻炎症反应,促进前列腺恢复,改善尿流动力学,控制病情程度。Objective To investigate the therapeutic effect of Guibai Huayu Capsules combined with Tamsulosin Hydrochloride Sustained-release Capsules in treatment of chronic prostatitis.Methods 130 Patients with chronic prostatitis admitted to Xinhua Hospital of Huainan Xinhua Medical Group from January 2021 to June 2023 were selected as the study objects,and randomly divided into control group and treatment group according to random drawing method,with 65 cases in each group.Patients in the control group took orally Tamsulosin Hydrochloride Sustained-release Capsules at a dose of 0.2 mg/time,once daily.Patients in the treatment group were given Guibai Huayu Capsules orally on the basis of the control group,3 capsules/time,3 times daily.Patients in both groups continued treatment for 4 weeks.The clinical efficacy,NIH-CPSI score,prostate volume,prostate transitional zone volume,urinary flow dynamics index,and prostatic fluid inflammatory factor were compared between two groups.Results The total effective rate of treatment group was 95.38%,which was higher than 83.08%of control group(P<0.05).After treatment,the pain score,voiding disorder score,quality of life score,and NIH-CPSI total score of both groups were lower than those before treatment(P<0.05),and the pain score,voiding disorder score,quality of life score,and NIH-CPSI total score of the treatment group were lower than those of the control group(P<0.05).After treatment,the prostate volume and the transitional zone volume of prostate in two groups were lower than those before treatment(P<0.05),and the prostate volume and the transitional zone volume of prostate in the treatment group were lower than those in the control group(P<0.05).After treatment,maximum urinary flow rate(MFR)and average urinary flow rate(AFR)of the two groups were increased,but residual urinary volume(PVR)of the two groups was decreased(P<0.05).And MFR and AFR of the treatment group were higher than those of the control group,but PVR was lower than those of the control group(P<0.05).After treatment

关 键 词：归柏化瘀胶囊 盐酸坦索罗辛缓释胶囊 慢性前列腺炎 NIH-CPSI评分 前列腺体积 最大尿流率 膀胱残余尿量 肿瘤坏死因子-α 

分 类 号：R983[医药卫生—药品]